Klinik und Poliklinik
für Innere Medizin II
Klinik und Poliklinik für Innere Medizin II
Direktor: Univ.-Prof. Dr. med. Roland. M. Schmid
direktion.med2@mri.tum.de

Arbeitsgruppe Prof. Dr. Maximilian Reichert

Unsere Arbeitsgruppe beschäftigt sich mit der Erforschung der Rolle epithelialer Plastizität in der Embryonalentwicklung, Regeneration und Tumorentstehung/-progression der Bauchspeicheldrüse sowie der Generierung von neuartigen Zellkultursystemen (z.B. Organoiden) von Patienten mit gastrointestinalen Tumorerkrankungen zur potentiellen Beurteilung von Prognose, Therapieansprechen und Resistenzen.

Team

  • Prof. Dr. med. Maximilian Reichert (Leitung)
  • Aurora Albanese (Technician)
  • Lisa Fricke, M.Sc. (Clinical trial coordination)
  • Peer Heuschneider (Voluntary Year in Scientific Work/FJN)
  • Dr. rer. nat. Valentina Leone (Postdoc)
  • Aristeidis Papargyriou, M.Sc. (PhD candidate)
  • Raphela Ranjan, M.Sc. (PhD candidate)
  • Aashreya Ravichandra, M.Sc. (PhD candidate)
  • Arlett Schäfer (Dr. med. sci. candidate)
  • Dr. rer. nat. Laura Schmidleitner (Postdoc)
  • Jasmin Schröder (Technician)
  • Akul Shastri, M.Sc. (PhD candidate)
  • Laura Ventura, M.Sc. (Staff scientist)
  • Patrick Wustrow (MD candidate)

Forschungsgebiet

Die Arbeitsgruppe von Maximilian Reichert beschäftigt sich mit der Rolle epithelialer Plastizität in der Embryonalentwicklung, Regeneration und Tumorentstehung/-progression der Bauchspeicheldrüse. Am Bespiel der Bauchspeicheldrüse werden zudem allgemeingültige Mechanismen von Tumorstreuung (Dissemination) sowie sekundärer Tumorformation (Kolonisierung und Metastasierung) erörtert. Letztlich ist es ein großes Anliegen der Gruppe, die gewonnenen Erkenntnisse in neuartige Therapiekonzepte umzusetzen.

englische Seite

Publikationen

  • Schneeweis C, Diersch S, Hassan Z, Krauß L, Schneider C, Lucarelli D, Falcomatà C, Steiger K, Öllinger R, Krämer OH, Arlt A, Grade M, Schmidt-Supprian M, Hessmann E, Wirth M, Rad R, Reichert M, Saur D, Schneider G. AP1/Fra1 confers resistance to MAPK cascade inhibition in pancreatic cancer. Cell Mol Life Sci. 2022 Dec 19;80(1):12. doi: 10.1007/s00018-022-04638-y
  • Schulz DAHO, Heilmaier M, Phillip V, Treiber M, Mayr U, Lahmer T, Mueller J, Demir IE, Friess H, Reichert M, Schmid RM, Abdelhafez M.  Accurate prediction of histological grading of intraductal papillary mucinous neoplasia using deep learning. Endoscopy. 2022 Nov 2. doi: 10.1055/a-1971-1274
  • S. Randriamanantsoa*, A. Papargyriou*, C. Maurer, K. Peschke, M. Schuster, K. Steiger, R. Öllinger, D. Saur, C. Scheel, R. Rad, E. Hannezo, A.R. Bausch*, M. Reichert*. Spatiotemporal dynamics of self-organised branching pancreatic cancer-derived organoids. Nat Commun. 2022 Sep 5;13(1):5219. doi: 10.1038/s41467-022-32806-y (* equally contributing)
  • Orben F, Lankes K, Schneeweis C, Hassan Z, Jakubowsky H, Krauß L, Boniolo F, Schneider C, Schäfer AP, Murr J, Schlag C, Kong B, Öllinger R, Wang C, Beyer G, Mahajan UM, Xue Y, Mayerle J, Schmid RM, Kuster B, Rad R, Braun CJ, Wirth M, Reichert M, Saur D, Schneider G. Epigenetic drug screening defines a PRMT5 inhibitor sensitive pancreatic cancer subtype. JCI Insight. 2022 Apr 19:e151353. doi: 10.1172/jci.insight.151353
  • Hennig A, Baenke F, Klimova A, Drukewitz S, Jahnke B, Brückmann S, Secci R, Winter C, Schmäche T, Seidlitz T, Bereuter JP, Polster H, Eckhardt L, Schneider SA, Brückner S, Schmelz R, Babatz J, Kahlert C, Distler M, Hampe J, Reichert M, Zeißig S, Folprecht G, Weitz J, Aust D, Welsch T, Stange DE. Detecting drug resistance in pancreatic cancer organoids guides optimized chemotherapy treatment. J Pathol. 2022 Apr 3. doi: 10.1002/path.5906
  • Kaltenbacher T, Löprich J, Maresch R, Weber J, Müller S, Oellinger R, Groß N, Griger J, de Andrade Krätzig N, Avramopoulos P, Ramanujam D, Brummer S, Widholz SA, Bärthel S, Falcomatà C, Pfaus A, Alnatsha A, Mayerle J, Schmidt-Supprian M, Reichert M, Schneider G, Ehmer U, Braun CJ, Saur D, Engelhardt S, Rad R. CRISPR somatic genome engineering and cancer modeling in the mouse pancreas and liver. Nat Protoc. 2022 Mar 14. doi: 10.1038/s41596-021-00677-0
  • Schneeweis C, Hassan Z, Ascherl K, Wirth M, Koutsouli S, Orben F, Krauß L, Schneider C, Öllinger R, Krämer OH, Rad R, Reichert M, Robles MS, Saur D, Schneider G. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Cancer Commun (Lond). 2022 Mar 7. doi: 10.1002/cac2.12280
  • Lier S, Sellmer A, Orben F, Heinzlmeir S, Krauß L, Schneeweis C, Hassan Z, Schneider C, Patricia Gloria Schäfer A, Pongratz H, Engleitner T, Öllinger R, Kuisl A, Bassermann F, Schlag C, Kong B, Dove S, Kuster B, Rad R, Reichert M, Wirth M, Saur D, Mahboobi S, Schneider G. A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorg Chem. 2022 Feb;119:105505. doi: 10.1016/j.bioorg.2021.105505
  • Falcomatà C, Bärthel S, Widholz SA, Schneeweis C, Montero JJ, Toska A, Mir J, Kaltenbacher T, Heetmeyer J, Swietlik JJ, Cheng JY, Teodorescu B, Reichert O, Schmitt C, Grabichler K, Coluccio A, Boniolo F, Veltkamp C, Zukowska M, Vargas AA, Paik WH, Jesinghaus M, Steiger K, Maresch R, Öllinger R, Ammon T, Baranov O, Robles MS, Rechenberger J, Kuster B, Meissner F, Reichert M, Flossdorf M, Rad R, Schmidt-Supprian M, Schneider G, Saur D. Selective multi-kinase inhibition sensitizes mesenchymal pancreatic cancer to immune checkpoint blockade by remodeling the tumor microenvironment. Nat Cancer. 2022 Jan 31. doi: 10.1038/s43018-021-00326-1
  • Peschke K, Jakubowsky H, Schäfer A, Maurer C, Lange S, Orben F, Bernad R, Harder FN, Eiber M, Öllinger R, Steiger K, Schlitter M, Weichert W, Mayr U, Phillip V, Schlag C, Schmid RM, Braren RF, Kong B, Demir IE, Friess H, Rad R, Saur D, Schneider G, Reichert M. Identification of treatment-induced vulnerabilities in pancreatic cancer patients using functional model systems. EMBO Mol Med. 2022 Feb 4:e14876. doi: 10.15252/emmm.202114876
  • Cintas C, Douche T, Dantes Z, Mouton-Barbosa E, Bousquet MP, Cayron C, Therville N, Pont F, Ramos-Delgado F, Guyon C, Garmy-Susini B, Cappello P, Burlet-Schiltz O, Hirsch E, Gomez-Brouchet A, Thibault B, Reichert M, Guillermet-Guibert J. Phosphoproteomics Identifies PI3K Inhibitor-selective Adaptive Responses in Pancreatic Cancer Cell Therapy and Resistance. Mol Cancer Ther. 2021 Dec;20(12):2433-2445. doi: 10.1158/1535-7163.MCT-20-0981
  • Hassan Z, Schneeweis C, Wirth M, Müller S, Geismann C, Neuß T, Steiger K, Krämer OH, Schmid RM, Rad R, Arlt A, Reichert M, Saur D, Schneider G. Important role of Nfkb2 in the KrasG12D-driven carcinogenesis in the pancreas. Pancreatology. 2021 Aug;21(5):912-919. doi: 10.1016/j.pan.2021.03.012
  • Zhang Z, Li H, Deng Y, Schuck K, Raulefs S, Maeritz N, Yu Y, Hechler T, Pahl A, Fernández-Sáiz V, Wan Y, Wang G, Engleitner T, Öllinger R, Rad R, Reichert M, Diakopoulos KN, Weber V, Li J, Shen S, Zou X, Kleeff J, Mihaljevic A, Michalski CW, Algül H, Friess H, Kong B. AG2-dependent nuclear import of RNA polymerase II constitutes a specific target of pancreatic ductal adenocarcinoma in the context of wild-type p53. Gastroenterology. 2021 Jul 22:S0016-5085(21)03281-9. doi: 10.1053/j.gastro.2021.07.030
  • Falcomata C, Barthel S, Ulrich A, Diersch S, Veltkamp C, Rad L, Boniolo F, Solar M, Steiger K, Seidler B, Zukowska M, Madej J, Wang M, Ollinger R, Maresch R, Barenboim M, Eser S, Tschurtschenthaler M, Mehrabi A, Roessler S, Goeppert B, Kind A, Schnieke A, Robles MS, Bradley A, Schmid RM, Schmidt-Supprian M, Reichert M, Weichert W, Sansom OJ, Morton JP, Rad R, Schneider G, Saur D. Genetic screens identify a context-specific PI3K/p27Kip1 node driving extrahepatic biliary cancer. Cancer Discov. 2021 Jul 19:candisc.0209.2021. doi: 10.1158/2159-8290.CD-21-0209
  • Doffo J, Bamopoulos SA, Köse H, Orben F, Zang C, Pons M, den Dekker AT, Brouwer RWW, Baluapuri A, Habringer S, Reichert M, Illendula A, Krämer OH, Schick M, Wolf E, van IJcken WFJ, Esposito I, Keller U, Schneider G, Wirth M. NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci U S A. 2022 Mar 1;119(9):e2105691119. doi: 10.1073/pnas.2105691119
  • Harder FN, Jungmann F, Kaissis GA, Lohöfer FK, Ziegelmayer S, Havel D, Quante M, Reichert M, Schmid RM, Demir IE, Friess H, Wildgruber M, Siveke J, Muckenhuber A, Steiger K, Weichert W, Rauscher I, Eiber M, Makowski MR, Braren RF. [18F]FDG PET/MRI enables early chemotherapy response prediction in pancreatic ductal adenocarcinoma. EJNMMI Res. 2021 Jul 28;11(1):70. doi: 10.1186/s13550-021-00808-4
  • Lesch S, Blumenberg V, Stoiber S, Gottschlich A, Ogonek J, Cadilha BL, Dantes Z, Rataj F, Dorman K, Lutz J, Karches CH, Heise C, Kurzay M, Larimer BM, Grassmann S, Rapp M, Nottebrock A, Kruger S, Tokarew N, Metzger P, Hoerth C, Benmebarek MR, Dhoqina D, Grünmeier R, Seifert M, Oener A, Umut Ö, Joaquina S, Vimeux L, Tran T, Hank T, Baba T, Huynh D, Megens RTA, Janssen KP, Jastroch M, Lamp D, Ruehland S, Di Pilato M, Pruessmann JN, Thomas M, Marr C, Ormanns S, Reischer A, Hristov M, Tartour E, Donnadieu E, Rothenfusser S, Duewell P, König LM, Schnurr M, Subklewe M, Liss AS, Halama N, Reichert M, Mempel TR, Endres S, Kobold S. T cells armed with C-X-C chemokine receptor type 6 enhance adoptive cell therapy for pancreatic tumours. Nat Biomed Eng. 2021 Jun 3. doi: 10.1038/s41551-021-00737-6
  • Lahmer T, Batres Baires G, Schmid RM, Wiessner JR, Ulrich J, Reichert M, Huber W, Sörgel F, Kinzig M, Rasch S, Mayr U. Penetration of Isavuconazole in Ascites Fluid of Critically Ill Patients. J Fungi (Basel). 2021 May 11;7(5):376. doi: 10.3390/jof7050376. PMID: 34064945
  • Breunig M, Merkle J, Wagner M, Melzer MK, Barth TFE, Engleitner T, Krumm J, Wiedenmann S, Cohrs CM, Perkhofer L, Jain G, Krüger J, Hermann PC, Schmid M, Madácsy T, Varga Á, Griger J, Azoitei N, Müller M, Wessely O, Robey PG, Heller S, Dantes Z, Reichert M, Günes C, Bolenz C, Kuhn F, Maléth J, Speier S, Liebau S, Sipos B, Kuster B, Seufferlein T, Rad R, Meier M, Hohwieler M, Kleger A. Modeling plasticity and dysplasia of pancreatic ductal organoids derived from human pluripotent stem cells. Cell Stem Cell. 2021 Apr 15:S1934-5909(21)00111-9. doi: 10.1016/j.stem.2021.03.005
  • Hartleben G, Schorpp K, Kwon Y, Betz B, Tsokanos FF, Dantes Z, Schäfer A, Rothenaigner I, Monroy Kuhn JM, Morigny P, Mehr L, Lin S, Seitz S, Tokarz J, Artati A, Adamsky J, Plettenburg O, Lutter D, Irmler M, Beckers J, Reichert M, Hadian K, Zeigerer A, Herzig S, Berriel Diaz M. Combination therapies induce cancer cell death through the integrated stress response and disturbed pyrimidine metabolism. EMBO Mol Med. 2021 Mar 5:e12461. doi: 10.15252/emmm.202012461
  • Liotta L, Lange S, Maurer HC, Olive KP, Braren R, Pfarr N, Burger S, Muckenhuber A, Jesinghaus M, Steiger K, Weichert W, Friess H, Schmid R, Algül H, Jost PJ, Ramser J, Fischer C, Quante AS, Reichert M, Quante M. PALLD mutation in a European family conveys a stromal predisposition for familial pancreatic cancer. JCI Insight. 2021 Mar 25;6(8):e141532. doi: 10.1172/jci.insight.141532
  • Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, Engleitner T, Öllinger R, Nomura A, Wirges N, Papargyriou A, Jahan Sarker RS, Ranjan RA, Dantes Z, Weichert W, Rustgi AK, Schmid RM, Rad R, Schneider G, Saur D, Reichert M. Mesenchymal Plasticity Regulated by Prrx1 Drives Aggressive Pancreatic Cancer Biology. Gastroenterology. 2021 Jan;160(1):346-361.e24. doi: 10.1053/j.gastro.2020.09.010
  • Lankes K, Hassan ZZ, Doffo MJ, Schneeweis C, Lier S, Öllinger R, Rad R, Krämer OH, Keller U, Saur D, Reichert M, Schneider G, Wirth M. Targeting the ubiquitin-proteasome system in a pancreatic cancer subtype with hyperactive MYC. Mol Oncol. 2020 Oct 25. doi: 10.1002/1878-0261.12835
  • Feldmann K, Maurer C, Peschke K, Teller S, Schuck K, Steiger K, Engleitner T, Öllinger R, Nomura A, Wirges N, Papargyriou A, Jahan Sarker RS, Ranjan RA, Dantes Z, Weichert W, Rustgi AK, Schmid RM, Rad R, Schneider G, Saur D, Reichert M. Mesenchymal plasticity regulated by Prrx1 drives aggressive pancreatic cancer biology. Gastroenterology. 2020 Sep 29:S0016-5085(20)35147-7. doi: 10.1053/j.gastro.2020.09.010
  • Dantes Z, Yen HY, Pfarr N, Winter C, Steiger K, Muckenhuber A, Hennig A, Lange S, Engleitner T, Öllinger R, Maresch R, Orben F, Heid I, Kaissis GA, Shi K, Topping GJ, Stögbauer F, Wirth M, Peschke K, Papargyriou A, Rezaee-Oghazi M, Feldmann K, Schäfer APG, Ranjan R, Lubeseder-Martellato C, Stange DE, Welsch T, Martignoni ME, Ceyhan GO, Friess H, Herner A, Liotta L, Treiber M, von Figura G, Abdelhafez M, Klare P, Schlag C, Algül H, Siveke JT, Braren RF, Weirich G, Weichert W, Saur D, Rad R, Schmid R, Schneider G, Reichert M. Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight. 2020 Jul 2:137809. doi: 10.1172/jci.insight.137809
  • Hidalgo-Sastre A, Desztics J, Dantes Z, Schulte K, Ensarioglu HK, Bassey-Archibong B, Öllinger R, Engleiter T, Rayner L, Einwächter H, Daniel JM, Altaee ASA, Steiger K, Lesina M, Rad R, Reichert M, von Figura G, Siveke JT, Schmid RM, Lubeseder-Martellato C. Loss of Wasl improves pancreatic cancer outcome. JCI Insight. 2020 May 21;5(10):e127275. doi: 10.1172/jci.insight.127275
  • Biederstädt A, Hassan Z, Schneeweis C, Schick M, Schneider L, Muckenhuber A, Hong Y, Siegers G, Nilsson L, Wirth M, Dantes Z, Steiger K, Schunck K, Langston S, Lenhof HP, Coluccio A, Orben F, Slawska J, Scherger A, Saur D, Müller S, Rad R, Weichert W, Nilsson J, Reichert M, Schneider G, Keller U. SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 2020 Jan 30. pii: gutjnl-2018-317856. doi: 10.1136/gutjnl-2018-317856
  • Li H, Shi K, Reichert M, Lin K, Tselousov N, Braren R, Fu D, Schmid R, Li J, Menze B. Differential Diagnosis for Pancreatic Cysts in CT Scans Using Densely-Connected Convolutional Networks. Conf Proc IEEE Eng Med Biol Soc. 2019 Jul;2019:2095-2098. doi: 10.1109/EMBC.2019.8856745
  • Marchand B, Pitarresi JR, Reichert M, Suzuki K, Laczkó D, Rustgi AK. PRRX1 isoforms cooperate with FOXM1 to regulate the DNA damage response in pancreatic cancer cells. Oncogene. 2019 Jan 31. doi: 10.1038/s41388-019-0725-6
  • Renz BW, Tanaka T, Sunagawa M, Takahashi R, Jiang Z, Macchini M, Dantes Z, Valenti G, White RA, Middelhoff MA, Ilmer M, Oberstein PE, Angele MK, Deng H, Hayakawa Y, Westphalen CB, Werner J, Remotti H, Reichert M, Tailor YH, Nagar K, Friedman RA, Iuga AC, Olive KP, Wang TC. Cholinergic Signaling via Muscarinic Receptors Directly and Indirectly Suppresses Pancreatic Tumorigenesis and Cancer Stemness. Cancer Discov. 2018 Sep 5. pii: CD-18-0046. doi: 10.1158/2159-8290.CD-18-0046
  • Reichert M*, Bakir B, Moreira L, Pitarresi JR, Feldmann K, Simon L, Suzuki K, Maddipati R, Rhim AD, Schlitter AM, Kriegsmann M, Weichert W, Wirth M, Schuck K, Schneider G, Saur D, Reynolds AB, Klein-Szanto AJ, Pehlivanoglu B, Memis B, Adsay NV, Rustgi AK*. Regulation of Epithelial Plasticity Determines Metastatic Organotropism in Pancreatic Cancer. Dev Cell. 2018 Jun 18;45(6):696-711.e8. doi: 10.1016/j.devcel.2018.05.025. *Corresponding authors
  • Ruess DA, Heynen GJ, Ciecielski KJ, Ai J, Berninger A, Kabacaoglu D, Görgülü K, Dantes Z, Wörmann SM, Diakopoulos KN, Karpathaki AF, Kowalska M, Kaya-Aksoy E, Song L, van der Laan EAZ, López-Alberca MP, Nazaré M, Reichert M, Saur D, Erkan MM, Hopt UT, Sainz B Jr, Birchmeier W, Schmid RM, Lesina M, Algül H. Mutant KRAS-driven cancers depend on PTPN11/SHP2 phosphatase. Nat Med. 2018 Jul;24(7):954-960. doi: 10.1038/s41591-018-0024-8
  • Moreira L, Bakir B, Chatterji P, Dantes Z, Reichert M, Anil Rustgi AK. Pancreas 3D organoids: current and future aspects as a research platform for personalized medicine in pancreatic cancer. Cellular and Molecular Gastroenterology and Hepatology (CMGH). doi: http://dx.doi.org/10.1016/j.jcmgh.2017.12.004
  • Das KK, Heeg S, Pitarresi JR, Reichert M, Bakir B, Takano S, Kopp JL, Wahl-Feuerstein A, Hicks P, Sander M, Rustgi AK. ETV5 regulates ductal morphogenesis with Sox9 and is critical for regeneration from pancreatitis. Dev Dyn. 2018 Mar 13. doi: 10.1002/dvdy.24626
  • Hassan Z, Schneeweis C, Wirth M, Veltkamp C, Dantes Z, Feuerecker B, Ceyhan GO, Knauer SK, Weichert W, Schmid RM, Stauber R, Arlt A, Krämer OH, Rad R, Reichert M, Saur D, Schneider G. MTOR inhibitor-based combination therapies for pancreatic cancer. Br J Cancer. 2018 Feb 6;118(3):366-377. doi: 10.1038/bjc.2017.421
  • Renz BW, Takahashi R, Tanaka T, Macchini M, Hayakawa Y, Dantes Z, Maurer HC, Chen X, Jiang Z, Westphalen CB, Ilmer M, Valenti G, Mohanta SK, Habenicht AJR, Middelhoff M, Chu T, Nagar K, Tailor Y, Casadei R, Di Marco M, Kleespies A, Friedman RA, Remotti H, Reichert M, Worthley DL, Neumann J, Werner J, Iuga AC, Olive KP, Wang TC. β2 Adrenergic-Neurotrophin Feedforward Loop Promotes Pancreatic Cancer. Cancer Cell. 2017 Dec 1. pii: S1535-6108(17)30510-X. doi: 10.1016/j.ccell.2017.11.007
  • Westphalen CB, Renz B, Reichert M, Rustgi AK, Wang TC. Cellular Plasticity and Heterogeneity in Pancreatic Regeneration and Malignancy. Cancer Cell & Microenvironment. 2016; 3: e1472. doi: 10.14800/ccm.1472
  • Schneeweis C, Wirth M, Saur D, Reichert M, Schneider G. Oncogenic KRAS and the EGFR loop in pancreatic carcinogenesis - a connection to licensing nodes. Small GTPases. 2016 Nov 23:0.  PMID: 27880072
  • Diersch S, Wirth M, Schneeweis C, Jörs S, Geisler F, Siveke JT, Rad R, Schmid RM, Saur D, Rustgi AK, Reichert M, Schneider G. Kras(G12D) induces EGFR-MYC cross signaling in murine primary pancreatic ductal epithelial cells. Oncogene. 2016 Jul 21;35(29):3880-6. doi: 10.1038/onc.2015.437
  • Heeg S, Das KK, Reichert M, Bakir B, Takano S, Caspers J, Aiello NM, Wu K, Neesse A, Maitra A, Iacobuzio-Donahue CA, Hicks P, Rustgi AK. ETS-Transcription Factor ETV1 Regulates Stromal Expansion and Metastasis in Pancreatic Cancer. Gastroenterology. 2016 Jun 16. pii: S0016-5085(16)34619-4. doi: 10.1053/j.gastro.2016.06.005
  • Lubeseder-Martellato C, Hidalgo-Sastre A, Hartmann C, Alexandrow K, Kamyabi-Moghaddam Z, Sipos B, Wirth M, Neff F, Reichert M, Heid I, Schneider G, Braren R, Schmid RM, Siveke JT. Membranous CD24 drives the epithelial phenotype of pancreatic cancer. Oncotarget. 2016 May 17. doi: 10.18632/oncotarget.9402
  • Westphalen CB, Takemoto Y, Tanaka T, Macchini M, Jiang Z, Renz BW, Chen X, Ormanns S, Nagar K, Tailor Y, May R, Cho Y, Asfaha S, Worthley DL, Hayakawa Y, Urbanska AM, Quante M, Reichert M, Broyde J, Subramaniam PS, Remotti H, Su GH, Rustgi AK, Friedman RA, Honig B, Califano A, Houchen CW, Olive KP, Wang TC. Dclk1 Defines Quiescent Pancreatic Progenitors that Promote Injury-Induced Regeneration and Tumorigenesis. Cell Stem Cell. 2016 Apr 7;18(4):441-55. doi: 10.1016/j.stem.2016.03.016
  • Takano S, Reichert M*, Bakir B, Das KK, Nishida T, Miyazaki M, Heeg S, Collins MA, Marchand B, Hicks PD, Maitra A, Rustgi AK*. Prrx1 isoform switching regulates pancreatic cancer invasion and metastatic colonization. Genes Dev. 2016 Jan 15;30(2):233-47. doi: 10.1101/gad.263327.115
  • Reichert M, Blume K, Kleger A, Hartmann D, von Figura G. Developmental Pathways Direct Pancreatic Cancer Initiation from Its Cellular Origin. Stem Cells Int. 2016; 2016:9298535. doi: 10.1155/2016/9298535
  • Ferreira MJ, McKenna LB, Zhang J, Reichert M, Bakir B, Buza EL, Furth EE, Bogue CW, Rustgi AK, Kaestner KH. Spontaneous Pancreatitis Caused by Tissue-Specific Gene Ablation of Hhex in Mice. Cell Mol Gastroenterol Hepatol. 2015 Sep 1;1(5):550-569. PMID: 26740970
  • Reichert M, Rhim AD, Rustgi AK. Culturing primary mouse pancreatic ductal cells. Cold Spring Harb Protoc. 2015 Jun 1;2015(6):pdb.prot078279. doi: 10.1101/pdb.prot078279
  • von Burstin J, Diersch S, Schneider G, Reichert M, Rustgi AK, Schmid RM. Detection of Tumor Suppressor Genes in Cancer Development by a Novel shRNA-Based Method. Mol Cancer Res. 2015 May;13(5):863-9. doi: 10.1158/1541-7786.MCR-14-0709
  • Worthley DL, Churchill M, Compton JT, Tailor Y, Rao M, Si Y, Levin D, Schwartz MG, Uygur A, Hayakawa Y, Gross S, Renz BW, Setlik W, Martinez AN, Chen X, Nizami S, Lee HG, Kang HP, Caldwell JM, Asfaha S, Westphalen CB, Graham T, Jin G, Nagar K, Wang H, Kheirbek MA, Kolhe A, Carpenter J, Glaire M, Nair A, Renders S, Manieri N, Muthupalani S, Fox JG, Reichert M, Giraud AS, Schwabe RF, Pradere JP, Walton K, Prakash A, Gumucio D, Rustgi AK, Stappenbeck TS, Friedman RA, Gershon MD, Sims P, Grikscheit T, Lee FY, Karsenty G, Mukherjee S, Wang TC. Gremlin 1 identifies a skeletal stem cell with bone, cartilage, and reticular stromal potential. Cell. 2015 Jan 15;160(1-2):269-84. doi: 10.1016/j.cell.2014.11.042
  • Bhattacharya S, Katlinski KV, Reichert M, Takano S, Brice A, Zhao B, Yu Q, Zheng H, Carbone CJ, Katlinskaya YV, Leu NA, McCorkell KA, Srinivasan S, Girondo M, Rui H, May MJ, Avadhani NG, Rustgi AK, Fuchs SY. Triggering ubiquitination of IFNAR1 protects tissues from inflammatory injury. EMBO Mol Med, 2014 Jan 30
  • Gao T, McKenna B, Li C, Reichert M, Nguyen J, Singh T, Yang C, Pannikar A, Doliba N, Edlund H, Matschinsky F, Stein R, Stanger BZ. Pdx1 maintains β-cell identity and function by repressing an a-cell identity. Cell Metabolism. 2014 Feb 4;19(2):259-71. doi: 10.1016/j.cmet.2013.12.002.
  • Kim J, Hoffman JP, Alpaugh RK, Rhim AD, Reichert M, Stanger BZ, Furth EE, Sepulveda AR, Yuan CX, Won KJ, Donahue G, Sands J, Gumbs AA, Zaret KS. An iPSC Line from Human Pancreatic Ductal Adenocarcinoma Undergoes Early to Invasive Stages of Pancreatic Cancer Progression. Cell Rep. 2013 Jun 19. doi:pii: S2211-1247(13)00269-6. 10.1016/j.celrep.2013.05.036
  • Reichert M, Takano S, Heeg S, Bakir B, Botta GP, Rustgi AK Gregory P. Botta, Anil K. Rustgi. Isolating Murine Pancreatic Ductal Cells using Magnetic Beads in Development, Regeneration and Cancer, Nature Protocols, 2013 Jun 20;8(7):1354-65. doi: 10.1038/nprot.2013.079
  • Botta GP, Reichert M, Reginato MJ, Heeg S, Rustgi AK, Lelkes PI. ERK2-regulated TIMP1 induces hyperproliferation of K-Ras(G12D)-transformed pancreatic ductal cells. Neoplasia. 2013 Apr;15(4):359-72
  • Diersch S, Wenzel P, Szameitat M, Eser P, Paul MC, Seidler B, Eser S, Messer M, Reichert M, Pagel P, Esposito I, Schmid RM, Saur D, Schneider G. Efemp1 and p27Kip1 modulate responsiveness of pancreatic cancer cells towards a dual PI3K/mTOR inhibitor in preclinical models. Oncotarget. 2013 Feb;4(2):277-88
  • Reichert M, Takano S, von Burstin J, Kim SB, Lee JS, Ihida-Stansbury K, Hahn C, Heeg S, Schneider G, Rhim AD, Stanger BZ, Rustgi AK. The Prrx1 homeodomain transcription factor plays a central role in pancreatic regeneration and carcinogenesis. Genes Dev. 2013 Feb 1;27(3):288-300. doi:10.1101/gad.204453.112
  • Conradt L, Henrich A, Wirth M, Reichert M, Lesina M, Algül H, Schmid RM, Krämer OH, Saur D, Schneider G. Mdm2 inhibitors synergize with topoisomerase II inhibitors to induce p53-independent pancreatic cancer cell death. Int J Cancer. 2013 May
  • Rhim AD, Mirek ET, Aiello NM, Maitra A, Bailey JM, McAllister F, Reichert M, Beatty GL, Rustgi AK, Vonderheide RH, Leach SD, Stanger BZ. EMT and dissemination precede pancreatic tumor formation. Cell. 2012 Jan 20;148(1-2):349-61. doi: 10.1016/j.cell.2011.11.025
  • Botta GP, Reginato MJ, Reichert M, Rustgi AK, Lelkes PI. Constitutive K-RasG12D activation of ERK2 specifically regulates 3D invasion of human pancreatic cancer cells via MMP-1. Mol Cancer Res. 2012 Feb;10(2):183-96. doi: 10.1158/1541-7786.MCR-11-0399
  • Reichert M, Rustgi AK. Pancreatic ductal cells in development, regeneration, and neoplasia. J Clin Invest. 2011 Dec;121(12):4572-8. doi: 10.1172/JCI57131.
  • Pinho AV, Rooman I, Reichert M, De Medts N, Bouwens L, Rustgi AK, Real FX. Adult pancreatic acinar cells dedifferentiate to an embryonic progenitor phenotype with concomitant activation of a senescence program that is present in chronic pancreatitis. Gut. 2011 Jul;60(7):958-66. doi: 10.1136/gut.2010.225920
  • von Burstin J, Reichert M, Wescott MP, Rustgi AK. The pancreatic and duodenal homeobox protein PDX-1 regulates the ductal specific keratin 19 through the degradation of MEIS1 and DNA binding. PLoS One. 2010 Aug 19;5(8).
  • Wescott MP, Rovira M, Reichert M, von Burstin J, Means A, Leach SD, Rustgi AK. Pancreatic Ductal Morphogenesis and the Pdx1 Homeodomain Transcription Factor. Mol Biol Cell 2009 Nov;20(22):4838-44
  • Schild C, Wirth M, Reichert M, Schmid RM, Saur D, Schneider G. PI3K signaling maintains c-myc expression to regulate transcription of E2F1 in pancreatic cancer cells. Mol Carcinog 2009
  • Hamacher R, Saur D, Fritsch R, Reichert M, Schmid RM, Schneider G. Casein kinase II inhibition induces apoptosis in pancreatic cancer cells. Oncol Rep 2007;18(3):695-701.
  • Schneider G, Reichert M, Saur D, Hamacher R, Fritsch R, Schmid RM. HDAC3 is linked to cell cycle machinery in MiaPaCa2 cells by regulating transcription of skp2. Cell Proliferation 2007;40(4):522-31.
  • Kolb S, Fritsch R, Saur D, Reichert M, Schmid RM, Schneider G. HMGA1 controls transcription of insulin receptor to regulate cyclin D1 translation in pancreatic cancer cells. Cancer Research 2007;67(10):4679-86.
  • Reichert M, Saur D, Hamacher R, Schmid RM, Schneider G. Phosphoinositide-3-kinase signaling controls S-phase kinase-associated protein 2 transcription via E2F1 in pancreatic ductal adenocarcinoma cells. Cancer Res. 2007 May 1;67(9):4149-56. 

PubMed

Wissenschaftliche Arbeiten

Bei Interesse an medizinischen (experimentellen) oder naturwissenschaftlichen Abschlussarbeiten (Bachelor, Master, PhD) bitte Kontaktaufnahme via E-Mail.


Kontakt

Leitung: Prof. Dr. med. Maximilian Reichert
Klinik und Poliklinik für Innere Medizin II
Klinikum rechts der Isar der TUM
Trogerstr. 32 (Raum 1.04), 81675 München
Tel.: (0 89) 41 40 - 27 45
Fax: (0 89) 41 40 - 24 69

E-Mail: maximilian.reichert@mri.tum.de